MedTrace Logo

Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC

NCT04920981 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 518

Last updated 2024-11-07

No results posted yet for this study

Summary

CLINATEZO cohort will evaluate overall survival, real world progression-free survival, best response and duration of treatment in patients with advanced, metastatic Small Cell Lung Cancer (SCLC) who received atezolizumab combined with chemotherapy part of the French Early Access Program (ATU). Subsequent treatments (treatment delivered immediately after treatment with atezolizumab and chemotherapy) will be recorded. Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients.

Conditions

Interventions

OTHER

atezolizumab

observational

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • GFPC

    collaborator UNKNOWN

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Nicolas GIRARD · Paris - Institut Curie

  • Lionel FALCHERO · Chalon-sur-Saône - CH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-02
Primary Completion
2021-11-24
Completion
2024-09-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920981 on ClinicalTrials.gov